SLC38A7 and brain neoplasm: Conventionally, dynamic PET imaging in preclinical brain tumors has been evaluated utilizing 2TCMs, descriptive of intratumoral perfusion and tracer binding, with agents targeting amino-acid transporters including [18F]FET and [18F]-fluciclovine, and molecular targets such as prostate specific membrane antigen (PSMA) small-molecule inhibitors 16,34.